How does T790M resistance occur?
The most common resistance mechanism results from the development of the so-called ‘gatekeeper’ T790M mutation in EGFR exon 20, which sterically hinders the binding of first- and second-generation TKIs to the ATP-binding site of EGFR.
Is Osimertinib 3rd generation?
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Thorac Cancer.
Is Osimertinib a TKI?
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) in patients failing previous TKI therapy.
What is treatment for EGFR mutation?
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the first-line treatment of choice for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC).
How is EGFR mutation detected?
In clinical practice, EGFR mutations are routinely detected using DNA extracted from primary or metastatic tumour tissue obtained during tumour biopsy or resection, which is typically formalin fixed and paraffin embedded (FFPE) (Ellison et al, 2013; Jung, 2013).
What are erlotinib and gefitinib?
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients.
What is the cost of Osimertinib?
In the U.S., osimertinib cost $17,028.90 per month, compared erlotinib (Tarceva, Genentech) at $9,390.44, gefitinib (Iressa, AstraZeneca) at $9,117.36 and afatinib (Gilotrif, Boehringer Ingelheim) at $9,785.72.
How long will Tagrisso work?
Tagrisso showed a 52% reduction in risk of central nervous system disease progression or death
| Tagrisso (n=279) | |
|---|---|
| Survival at 12 months (95% CI) | 89.1% (84.8-92.2) |
| Survival at 24 months (95% CI) | 74.2% (68.6-79.0) |
| Survival at 36 months (95% CI) | 53.7% (47.5-59.5) |
| CNS PFS (secondary endpoint)i,1 |
What does T790M stand for?
Jump to navigation Jump to search. T790M, also known as Thr790Met, is a gatekeeper mutation of the epidermal growth factor receptor (EGFR). The mutation substitutes a threonine (T) with a methionine (M) at position 790 of exon 20, affecting the ATP binding pocket of the EGFR kinase domain.
What is the T790M mutation?
From Wikipedia, the free encyclopedia T790M, also known as Thr790Met, is a gatekeeper mutation of the epidermal growth factor receptor (EGFR). The mutation substitutes a threonine (T) with a methionine (M) at position 790 of exon 20, affecting the ATP binding pocket of the EGFR kinase domain.
What is the T790M variant of EGFR?
Genetic variant. T790M, also known as Thr790Met, is a gatekeeper mutation of the epidermal growth factor receptor (EGFR). The mutation substitutes a threonine (T) with a methionine (M) at position 790 of exon 20, affecting the ATP binding pocket of the EGFR kinase domain.
What is the sagasafe ® EGFR T790M assay (CE-IVD)?
The SAGAsafe ® EGFR T790M assay (CE-IVD) achieves industry-leading superior performance by employing the patented ultrasensitive SAGAsafe ® digital PCR technology which in comparison to traditional approaches enhances true-positive signals and at the same time reduces false-positive signals.